| Interconversion between tumorigenic and differentiated states in acute myeloid leukemia MD McKenzie, M Ghisi, EP Oxley, S Ngo, L Cimmino, C Esnault, R Liu, ... Cell stem cell 25 (2), 258-272. e9, 2019 | 85 | 2019 |
| The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1 CL Carmichael, J Wang, T Nguyen, O Kolawole, A Benyoucef, ... Blood, The Journal of the American Society of Hematology 136 (8), 957-973, 2020 | 46 | 2020 |
| Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia Q Van Thillo, J De Bie, JA Seneviratne, S Demeyer, S Omari, ... Nature Communications 12 (1), 4164, 2021 | 13 | 2021 |
| Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy S Ngo, EP Oxley, M Ghisi, MM Garwood, MD McKenzie, HL Mitchell, ... Nature Communications 12 (1), 6546, 2021 | 7 | 2021 |
| 2000-MONOLINEAGE ORIGIN OF RELAPSE FOLLOWING MULTILINEAGE DIFFERENTIATION THERAPY OF ACUTE MYELOID LEUKEMIA R Dickins, S Ngo, E Oxley, M Ghisi, M McKenzie, M Garwood, ... Experimental Hematology 76, S42, 2019 | | 2019 |
| PF202 MONOLINEAGE ORIGIN OF AML RELAPSE FOLLOWING MULTILINEAGE DIFFERENTIATION THERAPY S Ngo, E Oxley, M Ghisi, M Mckenzie, M Garwood, S Jayakrishnan, ... HemaSphere 3, 53-54, 2019 | | 2019 |
| The Transcription Factor PU. 1 Controls a Reversible Differentiation Program in Acute Myeloid Leukemia MD McKenzie, M Ghisi, L Cimmino, M Erlichster, EP Oxley, C Liu, ... Blood 128 (22), 3930, 2016 | | 2016 |
| Uncovering Key Downstream Effectors of PU. 1 Tumor Suppression in Acute Myeloid Leukemia M Ghisi, MD McKenzie, EP Oxley, E Simankowicz, C Liu, A Dakic, SL Nutt, ... Blood, The Journal of the American Society of Hematology 128 (22), 2698-2698, 2016 | | 2016 |
| PU. 1 and maturational plasticity in acute myeloid leukaemia EP OXLEY Monash University, 0 | | |
